skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Bio-distribution and toxicity assessment of intravenously injected anti-HER2 antibody conjugated CdSe/ZnS quantum dots in Wistar rats

Original Research

(2241) Views  (1214) Full article downloads

Authors: Dhermendra K Tiwari, Takashi Jin, Jitendra Behari

Published Date February 2011 Volume 2011:6 Pages 463 - 475
DOI: http://dx.doi.org/10.2147/IJN.S15124

Dhermendra K Tiwari1, Takashi Jin2, Jitendra Behari1
1School of Environmental Sciences, Jawaharlal Nehru University, New Delhi, India; 2WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan

Abstract: Anti-HER2 antibody conjugated with quantum dots (anti-HER2ab-QDs) is a very recent fluorescent nanoprobe for HER2+ve breast cancer imaging. In this study we investigated in-vivo toxicity of anti-HER2ab conjugated CdSe/ZnS QDs in Wistar rats. For toxicity evaluation of injected QDs sample, body weight, organ coefficient, complete blood count (CBC), biochemistry panel assay (AST, ALT, ALP, and GGTP), comet assay, reactive oxygen species, histology, and apoptosis were determined. Wistar rat (8–10 weeks old) were randomly divided into 4 treatment groups (n = 6). CBC and biochemistry panel assay showed nonsignificant changes in the anti-HER2ab-QDs treated group but these changes were significant (P < 0.05) in QDs treated group. No tissue damage, inflammation, lesions, and QDs deposition were found in histology and TEM images of the anti-HER2ab-QDs treated group. Apoptosis in liver and kidney was not found in the anti-HER2ab-QDs treated group. Animals treated with nonconjugated QDs showed comet formation and apoptosis. Cadmium deposition was confirmed in the QDs treated group compared with the anti-HER2ab-QDs treated group. The QDs concentration (500 nM) used for this study is suitable for in-vivo imaging. The combine data of this study support the biocompatibility of anti-HER2ab-QDs for breast cancer imaging, suggesting that the antibody coating assists in controlling any possible adverse effect of quantum dots.

Keywords: cancer bioimaging, HER2, anti-HER2 antibody, quantum dots, comet assay




 

Other articles by Professor Jitendra Behari



Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Amino acid-responsive Crohn's disease: a case study
Erratum - Intracellular heavy metal nanoparticle storage
Amino acid management of Parkinson’s disease: a case study
A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
Advances in cancer therapy through the use of carbon nanotube-mediated targeted hyperthermia
Formation of silver microbelt structures by laser irradiation of silver nanoparticles in ethanol